Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.
Radu Crisan-DabijaCristina GrigorescuCristina-Alice PavelBogdan ArteneIolanda Valentina PopaAndrei CernomazAlexandru BurlacuPublished in: Canadian respiratory journal (2020)
Because viral respiratory infections and TB impede the host's immune responses, it can be assumed that their lethal synergism may contribute to more severe clinical evolution. Despite the rapidly growing number of cases, the data needed to predict the impact of the COVID-19 pandemic on patients with latent TB and TB sequelae still lies ahead. The trial is registered with NCT04327206, NCT01829490, and NCT04121494.
Keyphrases
- mycobacterium tuberculosis
- sars cov
- immune response
- coronavirus disease
- pulmonary tuberculosis
- clinical trial
- electronic health record
- big data
- respiratory syndrome coronavirus
- early onset
- dendritic cells
- phase ii
- randomized controlled trial
- skeletal muscle
- type diabetes
- current status
- adipose tissue
- hiv aids
- insulin resistance
- machine learning
- inflammatory response